Stocks Health care GALT
NASDAQ · Health careGalectin Therapeutics Inc (GALT)
It posted a net loss of $27.8M. At June 30, 2026 it held $13.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Galectin Therapeutics Inc
- Net worth
- Galectin Therapeutics Inc has a market value (market cap) of $340.9M at the latest share price, and shareholders' equity of -$138.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $23.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Galectin Therapeutics Inc's next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Galectin Therapeutics Inc does
Galectin Therapeutics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GALT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$30.8M | -$0.48 | n/a |
| 2024 | n/a | -$47M | -$0.76 | n/a |
| 2023 | n/a | -$41.1M | -$0.74 | n/a |
| 2022 | n/a | -$38.8M | -$0.65 | n/a |
| 2021 | n/a | -$30.5M | -$0.52 | n/a |
| 2020 | n/a | -$23.5M | -$0.41 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Galectin Therapeutics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 13, 2026
- October 13, 2026Additional proxy material DEFA14A
- October 13, 2026Proxy statement DEF 14A
- October 2, 2026Preliminary proxy statement PRE 14A
- August 14, 2026
- August 14, 2026
- August 4, 2026Activist stake changed SCHEDULE 13D/A
- August 4, 2026
- June 23, 2026
- May 15, 2026
Insider trades
What the people running Galectin Therapeutics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 31, 2026 | Uihlein Richard EDirector, 10% owner | Exercised optionsindirect | 31,825,235 | $95.5M |
| July 31, 2026 | Uihlein Richard EDirector, 10% owner | Exercised optionsindirect | 2,550,932 | $10.3M |
| July 14, 2026 | Jamil KhurramChief Medical Officer | Exercised options | 16,250 | $49.4K |
| July 14, 2026 | Jamil KhurramChief Medical Officer | Soldpre-planned (10b5-1) | 16,250 | $83.3K |
| June 29, 2026 | Jamil KhurramChief Medical Officer | Exercised options | 47,467 | $118.7K |
| June 29, 2026 | Jamil KhurramChief Medical Officer | Soldpre-planned (10b5-1) | 47,467 | $239.2K |
| June 29, 2026 | Shlevin Harold H.Director | Exercised options | 22,268 | $27.4K |
| June 29, 2026 | Shlevin Harold H.Director | Soldpre-planned (10b5-1) | 22,268 | $112.2K |
Who owns GALT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Richard E. Uihlein13D, may seek influence | 49.3% | August 4, 2026 |
| James C. Czirr13D, may seek influence with 2 related filers | 11.4% | December 1, 2023 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 98 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 2,988,353 | +2,189,116 |
| Vanguard Capital Management LLC | 2,168,065 | +201,523 |
| Geode Capital Management, LLC | 1,308,394 | +695,608 |
| Osaic Holdings, Inc. | 1,203,725 | +81,055 |
| Marshall Wace, Llp | 831,010 | -388,902 |
| Wealthspire Advisors, LLC | 721,788 | 0 |
| State Street Corp | 567,779 | +309,347 |
| Commonwealth Equity Services, LLC | 407,113 | +40,000 |
| Northern Trust Corp | 386,545 | +256,097 |
| Vanguard Fiduciary Trust Co | 366,476 | +62,235 |
| Vanguard Portfolio Management LLC | 327,766 | new |
| Two Sigma Investments, LP | 318,245 | -148,818 |
| LPL Financial LLC | 285,380 | +18,180 |
| Geneos Wealth Management Inc. | 240,427 | -500 |
| UBS Group AG | 219,319 | +39,578 |
| Retirement Guys Formula LLC | 211,053 | +23,991 |
| Citadel Advisors LLC | 198,701 | -91,659 |
| Sovran Advisors, LLC | 257,997 | +167 |
| Susquehanna International Group, Llp | 177,197 | -378,505 |
| National Bank of Canada | 167,900 | new |
Insiders
8 insiders reported holding 61,688,522 shares in total, about $208.5M at the last price.
| Holder | Shares |
|---|---|
| Uihlein Richard EDirector, 10% owner | 55,046,51944,713,843 held indirectly |
| 10X Fund, L.P.10% owner | 5,614,457 |
| Lewis JoelPresident and CEO, Director | 832,592 |
| Eldred KaryDirector | 65,682 |
| Freeman Kevin DDirector | 55,269 |
| Shlevin Harold H.Director | 37,329 |
| Jamil KhurramChief Medical Officer | 21,446 |
| Callicutt Jack WChief Financial Officer | 15,228 |
Questions about GALT
What does Galectin Therapeutics Inc do?
Galectin Therapeutics Inc is a company in the Health care sector, listed on NASDAQ as GALT. Its shares trade on NASDAQ under the ticker GALT.
What is Galectin Therapeutics Inc's net worth?
Galectin Therapeutics Inc has a market value (market cap) of $340.9M at the latest share price, and shareholders' equity of -$138.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Galectin Therapeutics Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $27.8M.
When did Galectin Therapeutics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the annual report to shareholders from October 13, 2026.
When is Galectin Therapeutics Inc's next earnings report?
Galectin Therapeutics Inc's next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare GALT with
Follow GALT
Get an email when Galectin Therapeutics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Galectin Therapeutics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.